
- Oncology NEWS International Vol 18 No 8
- Volume 18
- Issue 8
Yaupon locks up phase II Clearazide trial
Yaupon Therapeutics has completed enrollment for the second phase of its trial for Clearazide for early-stage cutaneous T-cell lymphoma.
Yaupon Therapeutics has completed enrollment for the second phase of its trial for Clearazide for early-stage cutaneous T-cell lymphoma.
The randomized study, slated for completion in 2010, has enrolled 260 patients from 13 cancer centers. Clearazide is a topical form of nitrogen mustard, an alkylating agent that works by inhibiting DNA replication.
Articles in this issue
about 16 years ago
New Doxil-based regimens don’t fly with FDA advisorsabout 16 years ago
Four steps to improve the profitability of your oncology practiceabout 16 years ago
Mathematical model predicts resistance to Herceptinabout 16 years ago
ASTRO issues guide on accelerated breast radiotherapyabout 16 years ago
Study renews breast ca link to migrainesabout 16 years ago
Sutent shows promise for brain metastases in NSCLC patientsabout 16 years ago
Abraxane, carboplatin pack one-two punch in two types of lung cancerabout 16 years ago
Discord prevails over pt privacy in clinical trialsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


















































































